Skip to content

Biodesix, Inc. BDSX Free cash flow

Free cash flow at other companies

NeoGenomics logo
NeoGenomicsNEO
-$13.14M+56.0%
Veracyte logo
VeracyteVCYT
$32.25M+810%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-$10.33M+65.3%
Personalis, Inc. logo
Personalis, Inc.PSNL
-$25.67M-25.4%
Guardant Health logo
Guardant HealthGH
Tempus AI, Inc. logo
Tempus AI, Inc.TEM

Other financials

Income statement

See full
Revenue$25.6M+42.3%
Operating income-$6.2M+32.1%
Net income-$7.8M+29.8%
EPS (diluted)-$0.81+46.7%

Balance sheet

See full
Cash & equivalents$25.6M+45.3%
Total debt$71.6M+15.0%
Total equity$9.1M-17.4%
Total assets$94.6M+9.7%

Cash flow

See full
Operating cash flow-$10.2M-18.2%
CapEx$81.0K+9.5%

Valuation

See full
Market cap$233.52M+476%
Enterprise value$279.56M+204%
P/S2.4×+1.9×

Profitability

See full
Operating margin-26%-7.5pp
Net margin-33.3%-9.3pp
FCF margin-26.8%-9.6pp

Returns & leverage

See full
Return on equity-316.5%
Debt / equity7.8×+2.2×
Current ratio2.8×+0.6×

Where this comes from

Calculated from Biodesix, Inc.’s reported figures.

The official record: Biodesix, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Biodesix, Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Biodesix, Inc.'s free cash flow?
Biodesix, Inc. (BDSX) reported free cash flow of -$10.25M in Q1 2026.
How has Biodesix, Inc.'s free cash flow changed year-over-year?
Biodesix, Inc.'s free cash flow decreased by 18.1% year-over-year, from -$8.68M to -$10.25M.
What is the long-term trend for Biodesix, Inc.'s free cash flow?
Over 4 years (2021 to 2025), Biodesix, Inc.'s free cash flow has grown at a -6.2% compound annual growth rate (CAGR), from -$31.27M to -$24.22M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.